

Domestic Net Sales

Three and six months ended June 30, 2017 and 2016 (unaudited)



DOMESTIC NET SALES: QTD			
(in millions)	Q2 2017	Q2 2016	Change
INTERVENTIONAL CARDIOLOGY	\$ 280	\$ 252	11%
CARDIAC RHYTHM MANAGEMENT	287	280	3%
ENDOSCOPY	225	189	19%
PERIPHERAL INTERVENTIONS	144	139	4%
UROLOGY AND PELVIC HEALTH	196	178	10%
NEUROMODULATION	125	115	9%
ELECTROPHYSIOLOGY	34	32	7%
TOTAL CORE BUSINESSES	\$ 1,291	\$ 1,185	9%

DOMESTIC NET SALES: YTD			
(in millions)	Q2 YTD 2017	Q2 YTD 2016	Change
INTERVENTIONAL CARDIOLOGY	\$ 558	\$ 491	14%
CARDIAC RHYTHM MANAGEMENT	571	536	6%
ENDOSCOPY	439	371	18%
PERIPHERAL INTERVENTIONS	286	274	4%
UROLOGY AND PELVIC HEALTH	379	339	12%
NEUROMODULATION	241	220	9%
ELECTROPHYSIOLOGY	66	63	5%
TOTAL CORE BUSINESSES	\$ 2,540	\$ 2,294	11%

Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

International Net Sales

Three and six months ended June 30, 2017 and 2016 (unaudited)



INTERNATIONAL NET SALES: QTD						INTERNATIONAL NET SALES: YTD					
(in millions)	Q2 2017	Q2 2016	Change		Constant Currency Basis	(in millions)	Q2 YTD 2017	Q2 YTD 2016	Change		Constant Currency Basis
			As Reported						As Reported		
INTERVENTIONAL CARDIOLOGY	\$ 323	\$ 327	(1)%		1%	INTERVENTIONAL CARDIOLOGY	\$ 636	\$ 637	—%		1%
CARDIAC RHYTHM MANAGEMENT	193	197	(2)%		—%	CARDIAC RHYTHM MANAGEMENT	372	374	(1)%		2%
ENDOSCOPY	175	172	2%		4%	ENDOSCOPY	341	322	5%		7%
PERIPHERAL INTERVENTIONS	129	119	8%		11%	PERIPHERAL INTERVENTIONS	248	227	9%		11%
UROLOGY AND PELVIC HEALTH	84	78	9%		12%	UROLOGY AND PELVIC HEALTH	163	144	13%		15%
NEUROMODULATION	29	20	42%		46%	NEUROMODULATION	54	36	50%		53%
ELECTROPHYSIOLOGY	33	28	17%		20%	ELECTROPHYSIOLOGY	64	56	15%		18%
TOTAL CORE BUSINESSES	\$ 966	\$ 941	3%		5%	TOTAL CORE BUSINESSES	\$ 1,878	\$ 1,796	5%		6%

Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

Worldwide Net Sales

Three and six months ended June 30, 2017 and 2016 (unaudited)



WORLDWIDE NET SALES: QTD					
(in millions)	Q2 2017	Q2 2016	Change		Constant Currency Basis
			As Reported		
INTERVENTIONAL CARDIOLOGY	\$ 603	\$ 579	4%		5%
CARDIAC RHYTHM MANAGEMENT	480	477	1%		2%
ENDOSCOPY	400	361	11%		12%
PERIPHERAL INTERVENTIONS	273	258	6%		7%
UROLOGY AND PELVIC HEALTH	280	256	10%		10%
NEUROMODULATION	154	135	14%		14%
ELECTROPHYSIOLOGY	67	60	12%		13%
TOTAL	\$ 2,257	\$ 2,126	6%		7%

WORLDWIDE NET SALES: YTD					
(in millions)	Q2 YTD 2017	Q2 YTD 2016	Change		Constant Currency Basis
			As Reported		
INTERVENTIONAL CARDIOLOGY	\$ 1,194	\$ 1,128	6%		7%
CARDIAC RHYTHM MANAGEMENT	943	910	4%		5%
ENDOSCOPY	780	693	12%		13%
PERIPHERAL INTERVENTIONS	534	501	6%		7%
UROLOGY AND PELVIC HEALTH	542	483	12%		13%
NEUROMODULATION	295	256	15%		16%
ELECTROPHYSIOLOGY	130	119	10%		11%
TOTAL	\$ 4,418	\$ 4,090	8%		9%

Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

Use of Non-GAAP Measures

To supplement Boston Scientific's consolidated financial statements presented on a U.S. GAAP basis, the Company discloses certain non-GAAP financial measures, including regional and divisional revenue growth rates that exclude the impact of changes in foreign currency exchange rates. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States (U.S. GAAP).

To calculate regional and divisional growth rates that exclude the impact of changes in foreign currency exchange rates, the Company converts actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period. The U.S. GAAP financial measure most directly comparable to this non-GAAP financial measure is growth rate percentages using net sales on a U.S. GAAP basis. A reconciliation of the non-GAAP financial measures included in this document to the corresponding GAAP measures is included in Boston Scientific's most recent earnings release filed with the SEC on Form 8-K. In addition, an explanation of the ways in which Boston Scientific management uses these supplemental non-GAAP measures to evaluate its business, and the substantive reasons why Boston Scientific management believes that these non-GAAP measures provide useful information to investors is included under "Use of Non-GAAP Financial Measures" in the Company's most recent earnings release filed with the SEC on Form 8-K. This additional non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with U.S. GAAP.